Bisphosphonate related osteonecrosis of the jaw onj is characterized by nonhealing exposed bone in the maxillofacial region in patients who have undergone bisphosphonate treatment. The special committee favors the term medicationrelated osteonecrosis of the jaw mronj. However, a serious sideeffect is bisphosphonate related osteonecrosis of the jaws bronj. In cancer patients bionj occurs mainly with long term, potent high dose intravenous bisphosphonates with an incident rate of 35%. One problem in identifying cases of bonj is that there is no universal agreement on a definition of the condition, compounded by the many terms used to describe it. Pdf bisphonates are used widely to treat osteoporosis, hyperglycemia of malignancy, bone metastasis of solid tumors. The restriction of bisphosphonate induced osteonecrosis to the jaw is thought to be related to the unique nature of the blood supply, structure, function and microbiology of the jaw. Pdf bisphosphonaterelated osteonecrosis of the jaw. In most cases the development of onj in those taking. Bisphosphonaterelated osteonecrosis of the jaws onj. Advisory task force on bisphosphonate related ostenonecrosis of the jaws. Utility of preoperative imaging diagnosis for a malignant tumor of the mandible. Possible association between diabetes and bisphosphonate.
Pdf bisphosphonaterelated osteonecrosis of the jaws. The aim was to evaluate the knowledge about bisphosphonaterelated osteonecrosis of the jaws bronj. Bisphosphonaterelated osteonecrosis of the jaws rev bras reumatol 2011. An update on bisphosphonaterelated osteonecrosis of the jaw. Approved by the board of trustees, september 25, 2006. It has been speculated that the medication, especially longterm i. Condition bisphosphonates, like alendronate fosamax, description care management tips osteonecrosis of the jaw onj is a condition where the jawbone is exposed and not. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate induced osteonecrosis of the jaw in a patient with multiple myeloma.
Bisphosphonaterelated osteonecrosis of the jaws bronj is a severe complication seen most frequently in patients on intravenous bisphosphonates treatment for malignant diseases. Bisphosphonates are frequently used worldwide mostly in osteoporosis and skeletal bone metastases. American association of oral and maxillofacial surgeons american association of oral and maxillofacial surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws 2009 update. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate induced osteonecrosis of the jaw. Bronj is a disease entity which has only been described relatively recently, and its multi. The incidence and susceptibility factors in cases of bisphosphonateinduced osteonecrosis of the jaw have been studied in patients with breast cancer and gynecological malignancies 16c. Osteonecrosis of the jaw an overview sciencedirect topics. Department of oral and maxillofacial radiology and research institute of oral science, college of dentistry, gangneungwonju national university, gangneung, korea. Its pathogenesis is not well understood and its management is difficult. This study tested hyperbaric oxygen hbo as an adjunct to surgery and antibiotics in the treatment of bisphosphonate related osteonecrosis of the jaw onj and evaluated its effects. Bisphosphonate use in cancer patients is associated with osteonecrosis of the jaws bisphosphonate induced osteonecrosis of the jaws bionj. Bisphosphonate related osteonecrosis of the jaw bronj can adversely affect quality of life, as it may produce significant morbidity. Apr 20, 2020 american association of oral and maxillofacial surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws.
The paget foundation for pagets disease of bone and related. However, there is limited scientific understanding about the association between osteonecrosis of the jaws and bisphosphonates. Bisphosphonate related osteonecrosis of the jaw rev bras reumatol 2012. Oral bisphosphonates and the risk for osteonecrosis of the.
Bisphosphonates and osteonecrosis of the jaws journal of. Usefulness of dwi in mri diagnosis of bisphosphonate related. We investigated the ct and dental panoramic radiograph dpr images for osteolysis. Reports of bisphosphonate related osteonecrosis of the jaw bronj were recognized as early as 2003. The following protocols have been developed by the bc cancer agency department of oral oncology. Legal liability from the perspective of the prescribing physician. Bisphosphonaterelated osteonecrosis of the jaws bronj core. Osteonecrosis of the jaw a potencial adverse effect of bisphosphonate treatment.
Additional important issues related to bisphosphonateassociated onj include. The aim of this study was to evaluate image characteristics of bisphosphonaterelated osteonecrosis of the jaws bronj and compare these with osteoradionecrosis orn. The underlying etiology is unclear and may be multifactorial. Position paper on bisphosphonaterelated osteonecrosis of the jaw2009 update. Harper and fung1, i wish to comment and raise questions on the recent editorial by kahn2 and article by etminan, et al 3.
Bisphosphonaterelated osteonecrosis of the jaw in patients with osteoporosis. Bisphosphonate associated osteonecrosis of the jaw is an important condition seen most commonly in oncology patients receiving highdose intravenous bisphosphonates. The reasons for the presentation of osteonecrosis in the jaws versus other parts of the skeleton are unknown at this time. Bisphosphonate related osteonecrosis of the jaw bronj is defined as exposed necrotic bone appearing in the jaws of patients treated by systemic iv or oral bps never irradiated in the head and neck area and that has persisted for more than 8 weeks. Bisphosphonate associated osteonecrosis of the jaw.
From the molecular viewpoint, bps are postulated to modulate the function of osteoclasts, reacting with a surface. Task force on bisphosphonaterelated osteonecrosis of the jaws. Harper and fung1, i wish to comment and raise questions on the recent. Imaging findings of bisphosphonateassociated osteonecrosis.
Bisphosphonaterelated osteonecrosis of the jaws bronj is among the most serious ones. Vescovi p, manfredi m, merigo e, guidotti r, meleti m, pedrazzi g, fornaini c, bonanini m, ferri t, nammour s 2012 early surgical laserassisted management of bisphosphonaterelated osteonecrosis of the jaws bronj. The management of bisphosphonaterelated osteonecrosis of the jaws bronj is emerging as a significant problem in the field of dentistry. The objective of the study was to evaluate whether diabetes mellitus dm may be a contributing factor in the development of bon.
Bps show high binding capacity to the bone matrix, especially in sites of active bone metabolism. Jan 11, 20 the prolonged use of bisphosphonates has been shown to cause a condition termed bisphosphonate related osteonecrosis of the jaws bronj. There is no test to measure onj risk, but some factors are known to raise this risk in very rare. In this article, we report two new cases of patients with. Experience with treating osteonecrosis of the jaw patients and recording medication histories were significantly greater in dental hospitals with 300 beds or university hospitals.
Diagnostic tissue sampling may exacerbate the process and is. Pdf bisphosphonate related osteonecrosis of the jaws. Bisphosphonaterelated osteonecrosis of the jaw bone. As a rheumatologist who has seen and managed bisphosphonate related osteonecrosis of the jaws fung e, medwatch case reports. Bisphosphonates are a class of agents whose efficacy in treating and preventing the skeletal complications associated with osteoporosis and malignant bone metastases has been well established.
Research article image findings of bisphosphonate related. Bisphosphonaterelated osteonecrosis of the jaws bronj is an extremely therapy resistant osteomyelitislike disease exclusively involving the jaw bones of patients in treatment with bisphosphonates bps. Twenty caucasian patients 19 women and 1 man were identified with a total of 24 lesions that satisfied the. A bibliographic search in medline, pubmed and the cochrane register of controlled clinical trials was performed between 2003 and 2010 by using the terms bisphosphonate and osteonecrosis of the jaw. The restriction of bisphosphonate induced osteonecrosis to the jaw is thought to be related to the unique nature of the blood supply, structure, function and microbiology of the jaw bones adamo et al. The condition is predominantly confined within the maxillofacial region. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw. Medicationrelated osteonecrosis of the jaw in patients with. This phenomenon, first observed after infusion of potent, nitrogencontaining bps for treating multiple myeloma and cancers involving bone metastasis, was termed bisphosphonaterelated osteonecrosis of the jaws. Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. Osteonecrosis of jaws onj might be old, dating back a century in the form of phossy jaw. Bisphosphonate related osteonecrosis of the jaws bronj is mainly observed in patients with multiple myeloma and bone metastasis from solid tumors receiving iv bisphosphonate. An identification of the fungal agent and its incrimination in the pathogenesis of bisphosphonates related osteonecrosis of the jaw. One centres on the bisphosphonate induced osteoclast inhibition and the other explains the process in terms of antiangiogenic mechanisms 2.
Bisphosphonaterelated osteonecrosis of the jaw in patients with. Bps antiresorptive activity substantially reduce fracture risk by 40%70% in osteoporosis patients, and improve quality of life in cancer patients by preventing skeletal complications. Bisphosphonaterelated osteonecrosis of the jaws bronj. Osteonecrosis of the jaw onj is a rare dental condition. Osteonecrosis of the jaws is recognized as a serious complication of bisphosphonate therapy, more commonly with the intravenous form of the drugs. Incidence of bisphosphonate related osteonecrosis of the jaws bronj in patients taking bisphosphonates for osteoporosis treatmenta grossly underestimated risk. Bisphosphonatesrelated osteonecrosis of the jaw bronj. In this article, we report two new cases of patients. Oral bisphosphonate related osteonecrosis of jaws bronj. Bisphosphonateassociated osteonecrosis of the jaw is an important condition seen most commonly in oncology patients receiving highdose intravenous bisphosphonates.
In 2003, bisphosphonaterelated osteonecrosis of the jaw bronj was first reported, with the demonstration of 36 bone lesions of the mandible andor maxilla in. Bisphosphonates bps are a class of drugs used to treat osteoporosis and malignant bone metastasis. Pdf bisphosphonaterelated osteonecrosis of the jaw bronj is a dramatic disintegration of the jaw that affects patients treated with. The change is justified to accommodate the growing number of osteonecrosis cases involving the maxilla and mandible associated with other antiresorptive denosumab. Drug related risk factors a bisphosphonate potency. Bisphosphonaterelated osteonecrosis of the jawsa case. Bp associated osteonecrosis of the jaws, bisphosphonate related osteonecrosis of the jaw, bp osteonecrosis, osteochemonecrosis, bisphossy jaw.
Early surgical laserassisted management of bisphosphonate. Bisphosphonateassociated osteonecrosis of the jaw the. Bisphosphonates are potent inhibitors of bone resorption, and are used in the treatment of osteoporosis and other diseases that cause bone mass loss, such as. Both try to address the predilection for this occurrence in the jaws. Oral bisphosphonaterelated osteonecrosis of the jaws. Bisphosphonates related osteonecrosis of the jaw bronj is related to the development of avascular osteonecrosis or osteochemonecrosis 1, 2.
Bisphosphonaterelated osteonecrosis of the jaw scielo. Osteonecrosis of the jaw is a serious complication associated with oral and intravenous bisphosphonate therapy. Lowdose bisphosphonates given either orally or intravenously in osteoporosis patients have not been causally linked to the development of osteonecrosis of the jaw. Dental care protocols bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Guidelines for the diagnosis of bisphosphonaterelated. American association of oral and maxillofacial surgeons position paper on bisphosphonate related osteonecrosis of the jaws. In this article, bisphosphonate associated osteonecrosis or bon will be the terms used to describe an osteonecrosis of the jaws secondary to bisphosphonate therapy. Surgical management of bisphosphonate related osteonecrosis of the jaws bronj has been performed in an attempt to increase healing rates of the affected cases.
Bisphosphonaterelated osteonecrosis bon of the jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure. Since intravenous administration leads to a higher drug exposure than the oral route, osteonecrosis related to oral bisphosphonate therapy is less common than that of related to intravenous forms such as zolendronate which is also more potent than oral bisphosphonates. American association of oral and maxillofacial surgeons. Condition bisphosphonates, like alendronate fosamax, description care management tips osteonecrosis of the jaw onj is a condition where the jawbone is exposed and not covered by gums. Although the methods of action are not yet completely understood, it is hypothesized that medicationassociated osteonecrosis of the jaw is related to a defect in jaw bone healing and remodelling. Page 1 medicationrelated osteonecrosis of the jaw 2014 update.
The change is justified to accommodate the growing number of osteonecrosis. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonateinduced osteonecrosis of the jaw in a patient with multiple myeloma. Endodontic implications of bisphosphonateassociated. Tosi p, zamagni e, cangini d, tacchetti p, offidani m, ronconi s, et al. A side effect called osteonecrosis of the jaw onj bone damage in the jaw has been reported uncommonly in patients receiving zoledronic acid zometa injections for cancer related. Pdf incidence of bisphosphonaterelated osteonecrosis of.
Bisphosphonates, drugs that decrease bone turnover by inhibiting osteoclastmediated bone resorption, are used to treat osteoporosis, paget disease, pain from osseous metastases, and malignancyrelated hypercalcemia. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw bronj. This case presentation focuses on a 50yearold woman with a 10year history of monthly zometa zoledronic acid use for treatment of multiple myeloma, resulting in bronj with a very unfavorable outcome. Despite these benefits, osteonecrosis of the jaws has recently emerged as a significant.
Department of oral and maxillofacial radiology and research institute of oral science, college of dentistry, gangneungwonju national university. The special committee favors the term medication related osteonecrosis of the jaw mronj. A mycotic infestation has been found in all of the 18 cases studied. Because these drugs have become more prevalent, there have been increased reports of bisphosphonaterelated osteonecrosis of the jaws bronj. Bisphosphonaterelated osteonecrosis of the jaws request pdf. Bisphosphonate dental care protocol bisphosphonates and osteonecrosis of the jaw.
Bisphosphonates and osteonecrosis of the jaw bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Medicationrelated osteonecrosis of the jaw wikipedia. The american college of prosthodontists agrees with the recommendation for the term, medicationrelated osteonecrosis of the jaw mronj suggested by the american association of maxillofacial surgeons aaoms to replace the previous, morespecific term, bisphosphonaterelated. The site of occurrence of the osteonecrosis is the jaws, and presentation occurs more frequently in the mandible than in the maxilla. American association of oral and maxillofacial surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws. Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well known complication at maxillofacial units around the world. Jan 04, 2012 surgical management of bisphosphonaterelated osteonecrosis of the jaws. In this group of selected patients with recurrent lithiasis and osteopenia the treatment with. Medication related osteonecrosis of the jaw mronj, which was first described in 2002, is a relatively uncommon but potentially serious side effect of treatment with osteoclast inhibitors, such as intravenous highpotency bisphosphonates and denosumab, which decrease the risk of skeletal related events in patients with cancer and metastatic bone disease. In 2002, the food and drug administration fda received first reports related to several patients with cancer, treated with the iv bisphosphonates bp, who developed osteonecrosis of the jaw. Bisphosphonate related osteonecrosis of the jaws the. Oral bisphosphonate related osteonecrosis of the jaw.
Bisphosphonaterelated osteonecrosis of the jaws bronj is an extremely therapy. However, prolonged bp use is associated with a significant dental complication termed bisphosphonaterelated osteonecrosis of the jaw bronj. Current or previous treatment with a bisphosphonate. Endodontic implications of bisphosphonate associated osteonecrosis of the jaws the guidance in this statement is not intended to substitute for a clinicians independent judgment in light of. The american association of oral and maxillofacial. Two broad theories have been articulated to explain the pathogenesis if bisphosphonate related osteonecrosis of the jaws bronj. One of the serious adverse effects of bisphosphonate therapy is bisphosphonaterelated osteonecrosis of the jaw bronj. Survey of korean dentists on the awareness on bisphosphonate. A bibliographic search in medline, pubmed and the cochrane register of controlled. Osteonecrosis of the jaws onj, also called antiresorptive agentinduced osteonecrosis of the jaw aronj and medicationrelated osteonecrosis of the jaw, is an oral complication in patients receiving bisphosphonate or rankl inhibitor therapy. Medication related osteonecrosis of the jaw guidance for the oncology multidisciplinary team 6 mronj in the adjuvant setting the frequency of mronj from oral bisphosphonates in the early breast cancer setting is 0.
885 1461 423 430 449 218 377 524 253 1067 564 1218 125 1259 360 402 137 1431 1141 911 814 871 454 322 1008 946 812 140 888 999 1021 622 1025 603 269 29